• 1
    Csuka D, Banati M, Rozsa C, Fust G, Illés Z. High anti-EBNA-1 IgG levels are associated with early-onset myasthenia gravis. Eur J Neurol 2012; 19:842846.
  • 2
    Niller HH, Wolf H, Minarovits J. Regulation and dysregulation of Epstein–Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 2008; 41:298328.
  • 3
    Ascherio A. Epstein–Barr virus in the development of multiple sclerosis. Exp Rev Neurother 2008; 8:331333.
  • 4
    Fust G. The role of the Epstein–Barr virus in the pathogenesis of some autoimmune disorders – similarities and differences. Eur J Microbiol Immunol 2011; 1:267278.
  • 5
    Ascherio A, Munger KL, Lennette ET et al. Epstein–Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001; 286:30833088.
  • 6
    Sundstrom P, Juto P, Wadell G et al. An altered immune response to Epstein–Barr virus in multiple sclerosis: a prospective study. Neurology 2004; 62:22772282.
  • 7
    Levin LI, Munger KL, Rubertone MV et al. Temporal relationship between elevation of Epstein–Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005; 293:24962500.
  • 8
    DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A. Epstein–Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 2006; 63:839844.
  • 9
    Levin LI, Munger KL, O'Reilly EJ, Falk KI, Ascherio A. Primary infection with the Epstein–Barr virus and risk of multiple sclerosis. Ann Neurol 2010; 67:824830.
  • 10
    Munger K, Levin L, O'Reilly E, Falk K, Ascherio A. Anti-Epstein–Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 2011; 17:11851193.
  • 11
    De Jager PL, Simon KC, Munger KL, Rioux JD, Hafler DA, Ascherio A. Integrating risk factors: HLA-DRB1*1501 and Epstein–Barr virus in multiple sclerosis. Neurology 2008; 70:11131118.
  • 12
    Sundstrom P, Nystrom M, Ruuth K, Lundgren E. Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis. J Neuroimmunol 2009; 215:102107.
  • 13
    Simon KC, van der Mei IA, Munger KL et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology 2010; 74:13651371.
  • 14
    McClain MT, Rapp EC, Harley JB, James JA. Infectious mononucleosis patients temporarily recognize a unique, cross-reactive epitope of Epstein–Barr virus nuclear antigen-1. J Med Virol 2003; 70:253257.
  • 15
    Toussirot E, Roudier J. Epstein–Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol 2008; 22:883896.
  • 16
    Esen BA, Yilmaz G, Uzun S et al. Serologic response to Epstein–Barr virus antigens in patients with systemic lupus erythematosus: a controlled study. Rheumatol Int 2012; 32:7983.
  • 17
    Zandman-Goddard G, Berkun Y, Barzilai O et al. Exposure to Epstein–Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann NY Acad Sci 2009; 1173:658663.
  • 18
    Truedsson L, Sturfelt G, Johansen P, Nived O, Thuresson B. Sharing of MHC haplotypes among patients with systemic lupus erythematosus from unrelated Caucasian multicase families: disease association with the extended haplotype (HLA-B8, SC01, DR17)]. J Rheumatol 1995; 22:18521861.
  • 19
    Podrebarac TA, Boisert DM, Goldstein R. Clinical correlates, serum autoantibodies and the role of the major histocompatibility complex in French Canadian and non-French Canadian Caucasians with SLE. Lupus 1998; 7:183191.
  • 20
    Marchini M, Antonioli R, Lleo A et al. HLA class II antigens associated with lupus nephritis in Italian SLE patients. Hum Immunol 2003; 64:462468.
  • 21
    Sundar K, Jacques S, Gottlieb P et al. Expression of the Epstein–Barr virus nuclear antigen-1 (EBNA-1) in the mouse can elicit the production of anti-dsDNA and anti-Sm antibodies. J Autoimmun 2004; 23:127140.
  • 22
    McClain MT, Poole BD, Bruner BF, Kaufman KM, Harley JB, James JA. An altered immune response to Epstein–Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum 2006; 54:360368.
  • 23
    Harley JB, James JA. Epstein–Barr virus infection induces lupus autoimmunity. Bull NYU Hosp Jt Dis 2006; 64:4550.
  • 24
    Poole BD, Templeton AK, Guthridge JM, Brown EJ, Harley JB, James JA. Aberrant Epstein–Barr viral infection in systemic lupus erythematosus. Autoimmun Rev 2009; 8:337342.
  • 25
    Marchini B, Dolcher MP, Sabbatini A, Klein G, Migliorini P. Immune response to different sequences of the EBNA I molecule in Epstein–Barr virus-related disorders and in autoimmune diseases. J Autoimmun 1994; 7:179191.
  • 26
    Goris A, Walton A, Ban M, Dubois B, Compston A, Sawcer S. A Taqman assay for high-throughput genotyping of the multiple sclerosis-associated HLA-DRB1*1501 allele. Tissue Antigens 2008; 72:401403.
  • 27
    Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 1988; 85:54095413.
  • 28
    Bartos A, Uray K, Hudecz F. New biotin derivatives for labeling and solubilizing IgG peptides. Biopolymers 2009; 92:110115.
  • 29
    Sundstrom P, Nystrom L, Jidell E, Hallmans G. EBNA-1 reactivity and HLA DRB1*1501 as statistically independent risk factors for multiple sclerosis: a case–control study. Mult Scler 2008; 14:11201122.
  • 30
    Waubant E, Mowry EM, Krupp L et al. Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 2011; 76:19891995.
  • 31
    Banwell B, Krupp L, Kennedy J et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007; 6:773781.
  • 32
    Sundqvist E, Sundstrom P, Linden M et al. Epstein–Barr virus and multiple sclerosis: interaction with HLA. Genes Immun 2012; 13:1420.
  • 33
    Irizar H, Munoz-Culla M, Zuriarran O et al. HLA-DRB1*15:01 and multiple sclerosis: a female association? Mult Scler 2012; 18:569577.
  • 34
    Santon A, Cristobal E, Aparicio M, Royuela A, Villar LM, Alvarez-Cermeno JC. High frequency of co-infection by Epstein–Barr virus types 1 and 2 in patients with multiple sclerosis. Mult Scler 2011; 17:12951300.
  • 35
    James JA, Neas BR, Moser KL et al. Systemic lupus erythematosus in adults is associated with previous Epstein–Barr virus exposure. Arthritis Rheum 2001; 44:11221126.
  • 36
    James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein–Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997; 100:30193026.
  • 37
    Poole BD, Gross T, Maier S, Harley JB, James JA. Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments. J Autoimmun 2008; 31:362371.
  • 38
    Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006; 59:499503.
  • 39
    Ulff-Moller CJ, Nielsen NM, Rostgaard K, Hjalgrim H, Frisch M. Epstein–Barr virus-associated infectious mononucleosis and risk of systemic lupus erythematosus. Rheumatology (Oxf) 2010; 49:17061712.
  • 40
    Moon UY, Park SJ, Oh ST et al. Patients with systemic lupus erythematosus have abnormally elevated Epstein–Barr virus load in blood. Arthritis Res Ther 2004; 6:R295302.
  • 41
    Kang I, Quan T, Nolasco H et al. Defective control of latent Epstein–Barr virus infection in systemic lupus erythematosus. J Immunol 2004; 172:12871294.
  • 42
    Lindsey JW, Hatfield LM, Crawford MP, Patel S. Quantitative PCR for Epstein–Barr virus DNA and RNA in multiple sclerosis. Mult Scler 2009; 15:153158.